GSK Reports the Results for Blenrep (belantamab mafodotin) in P-III Clinical Trial for the Treatment of Multiple Myeloma
Shots:
- The P-III (DREAMM-7) clinical trial evaluates the safety and efficacy of Blenrep (2.5mg/kg, Q3W, IV) + BorDex vs daratumumab + BorDex (SoC) in patients (n=494) with r/r multiple myeloma as 2L treatment in the ratio 1:1. The 1EP of the study includes PFS whereas the 2EPs include OS, DoR & minimal residual disease negativity rate
- The study met its 1EP of PFS and depicted a significantly extended time to disease progression or death with Blenrep + BorDex vs daratumumab + BorDex along with a clinically meaningful OS
- GSK’s DREAMM clinical development programme evaluates the potential of Blenrep as multiple myeloma treatment in trials incl. (DREAMM-7) & (DREAMM-8). The results from the (DREAMM-8) trial are expected by H2’24
Ref: GSK | Image: GSK
Related News:- Sosei Heptares Initiates to Reclaim Ownership GSK4381406 from GSK
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
